Risperidone: An analysis of the first three years in general use

International Clinical Psychopharmacology

Volumn 12, Issue SUPPL. 4, 1997, Pages

  Gutierrez Esteinou, Rolando ^a   Grebb, Jack A ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Chronic schizophrenia; First episode; Relapse prevention; Risperidone; Schizophrenia; Tardive dyskinesia; Treatment resistant schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; ZUCLOPENTHIXOL;

COGNITION; CONFERENCE PAPER; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEGATIVE SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DOPAMINE ANTAGONISTS; DRUG RESISTANCE; DYSKINESIA, DRUG-INDUCED; HOSPITALIZATION; HUMANS; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS;

EID: 0030881170     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199705002-00002     Document Type: Conference Paper

References (26)

1. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P (1993) Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 15:917-926.
2. Aguilar EJ, Matcheri SK, Martinez-Quiles MD, Hernández J, Gómez-Beneyto M, Schooler N (1994) Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 151: 1819-1821.
3. Albright P, Livingstone S, Keegan DL, Ingham M, Shrikhande S, Le Loner J (1996) Reduction of healthcare resources utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy. Clin Drug Invest 11:289-299.
4. Bondolfi G, Baumann P, Patris M, Maj JB, Billeter U (1995) A randomized, double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia [abstract]. Eur Neuropsychopharmacol 5:349.
5. Brecher M (1996) Long-term safety of risperidone [abstract P-15-1]. Eur Neuropsychopharmacol 6 (suppl 3): 170.
6. Carman J, Peuskens J, Vangeneugden A (1995) Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 10:207-213.
7. Chouinard G (1995) Effect of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 15 (suppl 1):365-445.
8. Chouinard G, Jones B, Remington G, et al. (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40.
9. Chouinard G, Ross-Chouinard A, Annable L, Jones BD (1980) Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 7:233.
10. Delay J, Deniker P (1952) Thirty-eight cases of psychoses treated over a long term and continued with 4560 RP [in French]. In: Compte Rendu du Congrés. Paris: Masson et Cie.
11. Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H (1996) Cognitive dysfunction in schizophrenia: a comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 6 (suppl 2):S13-S20.
12. Hafner H, Maurer K, Loffler W, Riecher-Rooler A (1993) The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 162:80-86.
13. Janssen PA (1970) The butyrophenone story. In: Discoveries in Biological Psychiatry. Edited by Ayd FJ. Philadelphia, Pennsylvania: Lippincott; pp 165-693.
14. 2 antagonistic properties. J Pharmacol Exp Ther 244:685-693.
15. Kane JM, Woerner M, Lieberman J (1988) Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 8 (suppl 4):52-56.
16. Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
17. Kopala LC (1997) Clinical experience in developing treatment regimens with the novel antipsychotic risperidone. Int Clin Psychopharmacol 12 (suppl 4):S11-S18.
18. Kopala LC, Fredrikson D, Good KP, Honer WG (1996) Symptoms in neuroleptic-naiive first-episode schizophrenia: response to risperidone. Biol Psychiatry 39:296-298.
19. Lindenmayer J-P (1995) New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatr Scand 91 (suppl 388):15-19.
20. Lindström E, Eriksson B, Hellgren A, von Knorring L, Eberhard G (1995) Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 17:402-412.
21. Marder SR, Meibach R (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
22. Möller H-J, Müller H, Borison RL, Schooler NR, Chouinard G (1995) A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Psychiatry and Clin Neurosci 245:45-49.
23. Peuskens J for the risperidone study group (1995) Risperidone in the treatment of chronic schizophrenic patients: a multinational, multicentre, double-blind, parallel group study versus haloperidol. Br J Psychiatry 166:712-726.
24. van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31: 67-72.
25. Weinberger DR, Gallhofer B (1977) Cognitive function in schizophrenia. Int Clin Psychopharmacol 12:S29-S36.
26. Wirshing W (1996) Treatment resistant schizophrenia: handling the switch. Schizophr Rev 4 (suppl 2): 7-8.